TY-0540
/ TYK Medicines
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
April 29, 2025
Study of TYK-00540 Tablets in Patients With Advanced Solid Tumors
(clinicaltrials.gov)
- P1/2 | N=180 | Recruiting | Sponsor: TYK Medicines, Inc
New P1/2 trial • Breast Cancer • HER2 Breast Cancer • HER2 Negative Breast Cancer • Hormone Receptor Breast Cancer • Hormone Receptor Positive Breast Cancer • Oncology • Solid Tumor
February 25, 2025
TYK Medicine’s CDK2 Inhibitor Receive Clinical Approval from CDE for Combination Therapy
(TYK Medicines Press Release)
- "TYK Medicine announced that its self-developed next-generation oral, highly potent small molecule CDK2 inhibitor, TYK-00540, has received formal approval from the Center for Drug Evaluation (CDE) of the National Medical Products Administration to proceed with Phase II clinical trial for combination therapy. The company is going to initiate the trial recently to accelerate the clinical development of TYK-00540....The Phase II clinical trial approval will further advance the development of TYK-00540 for CDK4/6 inhibitor-resistant breast cancer and prostate cancer indications, positioning it as a promising candidate in TYK Medicine’s oncology pipeline to solve the unmet medical needs."
New P2 trial • Breast Cancer • Prostate Cancer
February 07, 2024
ASOTIAPWST: A Study of TYK-00540 in Adult Patients With Solid Tumors
(clinicaltrials.gov)
- P1 | N=156 | Recruiting | Sponsor: TYK Medicines, Inc
New P1 trial • Oncology • Solid Tumor
March 14, 2023
TY-0540, a highly potent CDK2/4/6 inhibitor, attenuates acquired resistance against CDK4/6 inhibition
(AACR 2023)
- "To test the effectiveness of the clinical candidate compound on CDK4/6i resistance models, two Palbociclib resistant cell populations (T47D-R, HCC1428-R) were in-house generated via gradient exposure of the cells to Palbociclib. #Meihua Li and Chengshan Niu contributed equally to this work. *Jun Li, Meihua Li and Chengshan Niu are the correspondent authors."
Preclinical • Breast Cancer • HER2 Breast Cancer • Oncology • Solid Tumor • CCNE1 • CDK1 • CDK7 • CDK9 • E2F1 • ER • FOXM1 • HER-2 • MYC
1 to 4
Of
4
Go to page
1